Actuate, a global provider of vision-based AI monitoring solutions, has announced the appointment of Ken Francis as CEO.

About Actuate Therapeutics, Inc. Actuate is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers. Actuate’s ...

Francis will lead Actuate’s continued global expansion, strengthen its channel partnerships, and advance its position as a ...

Companies will discuss how Lantern’s AI platform is being leveraged for the identification and development of enrichment ...

Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing therapeutics which target cancers and neurodegenerative diseases. It offers treatment for ...

This page features the latest news about the Actuate Therapeutics stock. Actuate to Participate in Lantern's Pharma Webinar on AI-Driven Drug Development Companies will discuss how Lantern's AI ...

Earnings Per Share (TTM) A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding. Market Capitalization Reflects the total ...

stake increases to 5.05% -Signs a regional partnership with the Nasdaq-listed Actuate Corporation, an enterprise reporting applications provider, to collaborate in the Asia Pacific region.

Ms Rudolph has 15+ years of experience in the Customer Experience industry - most recently with Oracle Corporation where she headed up the Customer Experience team focused on Financial Services & ...